Novartis announced today that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.
[More]
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
[More]
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2013.
[More]
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
[More]
Regeneron Pharmaceuticals, Inc. today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi.
[More]
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol.
[More]
For many people who have fibromyalgia, even the thought of exercising is painful. Yet a new study from Wake Forest Baptist Medical Center shows that exercise does not worsen the pain associated with the disorder and may even lessen it over time.
[More]
Solving the structure of a critical human molecule involved in cancer, scientists at The Scripps Research Institute have found what they call a good example of structural conservation-dissimilar genes that keep very similar shapes.
[More]
Study findings may help guide rituximab dosing regimens for patients with rheumatoid arthritis.
[More]
A gas associated with the smell of rotten eggs has proven to effectively reduce joint swelling, in research which could lead to advances in the treatment of arthritis.
[More]
A new study led by researchers at the Graduate Entry Medical School (GEMS), University of Limerick (UL) has found that people suffering from gout and elevated serum uric acid have significantly increased risks of death.
[More]
Surgery is often recommended for skin cancers, but older, sicker patients can endure complications as a result and may not live long enough to benefit from the treatment.
[More]
The tiny thymus teaches the immune system to ignore the teeming, foreign bacteria in the gut that helps you digest and absorb food, researchers say.
[More]
Opsona Therapeutics Limited, the innate immune drug development company, today announced that it has raised €33 million (US $ 43 million) in an oversubscribed Series C financing.
[More]
An upcoming symposium will offer highlights of the 150-year history of Hospital for Special Surgery and at the same time provide a fascinating look at the evolution of medicine from the "Dark Ages" of the Civil War period to modern medicine as we know it today.
[More]
Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.
[More]
Knee replacement surgery has traditionally been performed using off-the-shelf implants because of the limitations of technology. As with most industries, evolution does occur.
[More]
Scientists from the Manchester Collaborative Centre for Inflammation Research have discovered why a particular cancer drug is so effective at killing cells.
[More]
Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype.
[More]
Hospital for Special Surgery in New York City has received a $5.6 million grant from The Tow Foundation to establish the Hospital for Special Surgery Genomics Center.
[More]